HPL launches anti-cancer medicine in Bangladesh

UNB :
Bangladesh-based Healthcare Pharmaceuticals Ltd. (HPL) and American Eli Lilly & Company on Friday launched Cyramza™ (ramucirumab injection, 10 mg/mL solution) in the country.
Cyramza™ is an anti-cancer medicine approved as a single agent or in combination with other agents for cancers arising from the stomach, lungs, liver, or large bowel that has spread to distant parts of the body.
Top officials of HPL and Eli Lilly & Company launched the medicine at a programme at a city hotel, said a press release.
Speaking about the medicine’s benefits to patients, Luca Visini, MD of Eli Lilly and Company India, said, “Cancer impacts the lives of many people every year. We are pleased to bring to Bangladesh an option for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) and second-line treatment for people living with the burden of gastric cancer.”
“We believe this will help us in moving several steps ahead in our collective goal to make lung and gastric cancer a less formidable challenge and a condition that can be managed,” he added.